Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"SK Chemicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA\u2019s Human Medicines Committee Begins Review of Conditional MAA for Skycovion Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Chemicals"},{"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of Celltrion Antibody Regdanvimab for Covid-19 Share","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Announces Positive Top-Line Results from Global Phase III Trial of Regdanvimab (CT-P59)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"}]

SK Chemicals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

EMA’s Human Medicines Committee Begins Review of Conditional MAA for Skycovion Covid-19 vaccine

Details:

Skycovion,a vaccine for protecting against Covid-19 has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2.

Lead Product(s): SARS-CoV-2 Surface Spike Protein,Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Skycovion

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 20, 2022

ASK
US

Upload
your Pipeline Activity

Celltrion

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Celltrion Announces Positive Top-Line Results from Global Phase III Trial of Regdanvimab (CT-P59)

Details:

Top-line results also showed CT-P59 to have a positive safety profile, with no clinically meaningful differences between patients treated with CT-P59 (40mg/kg) and placebo-treated patients.

Lead Product(s): Regdanvimab

Therapeutic Area: Infections and Infectious Diseases Product Name: CT-P59

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2021

ASK
US

Upload
your Pipeline Activity

Celltrion

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

EMA Starts Rolling Review of Celltrion Antibody Regdanvimab for Covid-19 Share

Details:

Regdanvimab is a monoclonal antibody with activity against COVID-19. A monoclonal antibody is a type of protein that has been designed to attach to a specific structure (called an antigen).

Lead Product(s): Regdanvimab

Therapeutic Area: Infections and Infectious Diseases Product Name: CT-P59

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2021

ASK
US

Upload
your Pipeline Activity

SK Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

Details:

SK Bioscience will add significant production capacity under this new agreement. Novavax recently reported positive interim efficacy results for the NVX-CoV2373 in an ongoing Phase 3 trial in the U.K and is also currently conducting a Phase 3 trial in the U.S. and Mexico.

Lead Product(s): NVX-COV2373,Matrix-M1

Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Novavax

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration February 15, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY